APA (7th ed.) Citation

Bois, A. d., Marth, C., Pfisterer, J., Harter, P., Hilpert, F., Zeimet, A. G., & Sehouli, J. (2012). Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer. International journal of gynecological cancer, 22(2), 182-185. https://doi.org/10.1136/ijgc-00009577-201202000-00005

Chicago Style (17th ed.) Citation

Bois, Andreas du, Christian Marth, Jacobus Pfisterer, Philipp Harter, Felix Hilpert, Alain G. Zeimet, and Jalid Sehouli. "Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer." International Journal of Gynecological Cancer 22, no. 2 (2012): 182-185. https://doi.org/10.1136/ijgc-00009577-201202000-00005.

MLA (9th ed.) Citation

Bois, Andreas du, et al. "Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer." International Journal of Gynecological Cancer, vol. 22, no. 2, 2012, pp. 182-185, https://doi.org/10.1136/ijgc-00009577-201202000-00005.